Pharmacokinetics of deferiprone in patients with β-thalassaemia: Impact of splenectomy and iron status

Clinical Pharmacokinetics

Volumn 50, Issue 1, 2011, Pages 41-50

  Limenta, Lie Michael George ^a   Jirasomprasert, Totsapol ^a   Jittangprasert, Piyada ^b   Wilairat, Prapin ^a   Yamanont, Praveena ^a   Chantharaksri, Udom ^a   Fucharoen, Suthat ^c   Morales, Noppawan Phumala ^a  

^a Mahidol University   (Thailand)

^b SRINAKHARINWIROT UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

, pharmacokinetics; Beta thalassaemia; Chelating agents; Deferiprone; Iron chelating agents; Iron overload; Spleen; Thalassaemia

Indexed keywords

DEFERIPRONE; DEFERIPRONE GLUCURONIDE; DRUG METABOLITE; FERRITIN; GPO L1; HEMOGLOBIN E; IRON; IRON CHELATE; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BETA THALASSEMIA; BLOOD SAMPLING; DIET RESTRICTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG EFFICACY; DRUG URINE LEVEL; FEMALE; GLUCURONIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; MAXIMUM PLASMA CONCENTRATION; MULTIPLE LINEAR REGRESSION ANALYSIS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLENECTOMY; URINARY EXCRETION; URINE VOLUME;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BETA-THALASSEMIA; BLOOD TRANSFUSION; FEMALE; FERRITINS; HEMOGLOBIN E; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; PYRIDONES; SPLENECTOMY; TRANSFERRIN;

EID: 78649929842     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11536630-000000000-00000     Document Type: Article

References (42)

1. Weatherall DJ, Clegg JB. The thalassaemia syndromes. 4th ed. Oxford: Blackwell Science, 2001.
2. Fucharoen S, Winichagoon P. Clinical and hematologic aspects of hemoglobin E beta-thalassemia. Curr Opin Hematol 2000; 7: 106-12.
3. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ 2001; 79: 704-12.
4. Viprakit V, Lee-Lee C, Chong QT, et al. Iron chelation therapy in the man- agement of thalassemia: the Asian perspectives. Int J Hematol 2009; 90: 435-45.
5. Vichinsky EP. Changing patterns of thalassemia worldwide. Ann NY Acad Sci 2005; 1054: 18-24.
6. Cohen AR, Galanello R, Pennell DJ, et al. Thalassemia. Hematology Am Soc Hematol Educ Program 2004; 14-34
7. Olivieri NF. The X-thalassemias. N Engl J Med 1999; 341: 99-109
8. Singh S, Epemolu RO, Dobbin PS, et al. Urinary metabolic profiles in human and ratof 1,2-dimethyl- and 1,2-diethyl-substituted3-hydroxypyridin-4- ones. Drug Metab Dispos 1992; 20: 256-61.
9. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major. Blood 2006; 107: 3733-7.
10. Piga A, Gaglioti C, Fogliacco E, et al. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88: 489-96.
11. Rombos Y, Tzanetea R, Konstantopoulos K, et al. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Haematologica 2000; 85: 115-7.
12. Kontoghiorghes GJ, Goddard JG, Bartlett AN, et al. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Pharmacol Ther 1990; 48: 255-61.
13. Hoffbrand AV, Al-Refaie F, Davis B, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998; 91: 295-300.
14. Diav-Citrin O, Atanackovic G, Koren G. An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major. Ther Drug Monit 1999; 21: 74-81.
15. Jirasomprasert T, Morales NP, Limenta LMG, et al. Pharmaco/ferrokinetic- related pro-oxidant activity of deferiprone in b-thalassemia. Free Radic Res 2009; 43: 485-91.
16. Fucharoen S, Ketvichit P, Pootrakul P, et al. Clinical manifestation of beta- thalassemia/hemoglobin E disease. J Pediatr Hematol Oncol 2000; 22: 552-7.
17. Angchaisuksiri P, Atichartakarn V, Aryurachai K, et al. Hemostatic and thrombotic markers in patients with hemoglobin E/beta-thalassemia disease. Am J Hematol 2007; 82: 1001-4.
18. Phrommintikul A, Sukonthasarn A, Kanjanavanit R, et al. Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia. Heart 2006; 92: 1467-72.
19. Aessopos A, Farmakis D, Tsironi M, et al. Hemodynamic assessment of splenomegaly in beta-thalassemia patients undergoing splenectomy. Ann Hematol 2004; 83: 775-8.
20. Graziano JH, Piomelli S, Hilgartner M, et al. Chelation therapy in beta- thalassemia major: III. The role of splenectomy in achieving iron balance. J Pediatr 1981; 99: 695-9.
21. Fiorelli G, Fargion S, Piperno A, et al. Iron metabolism in thalassemia inter- media. Haematologica 1990; 75 Suppl. 5: 89-95.
22. Seshadri R, Colebatch JH, Fisher R. Urinary iron excretion in thalassaemia after desferrioxamine administration. Arch Dis Child 1974; 49: 195-9.
23. Limenta LM, Jirasomprasert T, Tankanitlert J, et al. UGT1A6 genotype- related pharmacokinetics of deferiprone (L1) in healthy volunteers. Br J Clin Pharmacol 2008; 65: 908-16.
24. Jittangprasert P, Wilairat P, Pootrakul P. Comparison of colorimetry and electrothermal atomic absorption spectroscopy for the quantification of non-transferrin bound iron in human sera. Southeast Asian J Trop Med Public Health 2004; 35: 1039-44.
25. Recommendations for measurement of serum iron in human blood. Br J Haematol 1978; 38: 291-4.
26. Mebius RE, Kraal G. Structure and function of the spleen. Nat Rev Immunol 2005; 5: 606-16.
27. Vatanavicharn S, Anuwatanakulchai M, Tuntawiroon M, et al. Iron absorp- tion in patients with beta-thalassaemia/haemoglobin E disease and the effect of splenectomy. Acta Haematol 1983; 69: 414-6.
28. Wasi P, Pravatmuang P. Serum iron in thalassemia and the effect of sple- nectomy. J Med Assoc Thai 1979; 62: 532-7.
29. Pootrakul P, Rugkiatsakul R, Wasi P. Increased transferrin iron saturation in splenectomized thalassaemic patients. Br J Haematol 1980; 46: 143-5.
30. Pootrakul P, Vongsmasa V, La-ongpanich P, et al. Serum ferritin levels in thalassemias and the effect of splenectomy. Acta Haematol 1981; 66: 244-50.
31. Tavazzi D, Duca L, Graziadei G, et al. Membrane-bound iron contributes to oxidative damage of beta-thalassaemia intermedia erythrocytes. Br J Hae-matol 2001; 112: 48-50.
32. Domenica Cappellini M, Tavazzi D, Duca L, et al. Non-transferrin-bound iron, iron-related oxidative stress and lipid peroxidation in beta-thalassemia intermedia. Transfus Sci 2000; 23: 245-6.
33. Anderson GJ. Non-transferrin-bound iron and cellular toxicity. J Gastro- enterol Hepatol 1999; 14: 105-8.
34. Kontoghiorghes GJ. Iron mobilization from transferrin and non-transferrin- bound-ironbydeferiprone: implications in the treatmentofthalassemia, anemia of chronic disease, cancer and other conditions. Hemoglobin 2006; 30: 183-200.
35. Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 2000; 23: 185-92.
36. De Feo TM, Fargion S, Duca L, et al. Non-transferrin-bound iron in alcohol abusers. Alcohol Clin Exp Res 2001; 25: 1494-9.
37. Lee DH, Liu DY, Jacobs Jr DR, et al. Common presence of non-transferrin- bound iron among patients with type2diabetes. Diabetes Care 2006; 29: 1090-5.
38. Kontoghiorghes GJ, Kolnagou A. Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators. Curr Med Chem 2005; 12: 2695-709.
39. Kontoghiorghes GJ, Pattichis K, Neocleous K, et al. The design and devel- opment of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem 2004; 11: 2161-83.
40. Haverfield EV, Weatherall DJ, Graber AY, et al. Pharmacogenomics of de- feriprone metabolism [abstract]. Blood 2005; 106 (11): Abstract 2703.
41. Benoit-Biancamano MO, Connelly J, Villeneuve L, et al. Deferiprone glucur- onidation by human tissues and recombinant UGT1A6: an in vitro investigation of genetic and splice variants. Drug Metab Dispos 2009; 37 (2): 322-9.
42. Kontoghiorghes GJ, Bartlett AN, Sheppard L, et al. Oral iron chelation therapy with deferiprone: monitoring of biochemical, drug and iron excretion changes. Arzneimittelforschung 1995; 45: 65-9